


Figure S1. Changes in the circulating tumor DNA concentration post-NAC compared with measured pre-NAC in (A) NAC-sensitive and (B) resistant patient groups. The statistical analyses were performed using the Mann-Whitney U test.  $P < 0.05$  was considered to indicate a statistically significant difference. NAC, neoadjuvant chemotherapy.

A NAC-sensitive cases



B NAC-resistant cases




Figure S2. Genotype and VAF of *TP53* mutation in NAC-sensitive and resistant patient groups. Nine sites of *TP53* mutation were detected. In NAC-sensitive cases, VAF in post-NAC was decreased as compared to pre-NAC. In NAC-resistant cases, VAF in post-NAC was increased compared as to pre-NAC. VAF, variant allele frequency; NAC, neoadjuvant chemotherapy.

Case No.	Genotype of <i>TP53</i>	<i>TP53</i> VAF (%)		response to chemotherapy
		pre	post	
1	R248W	4.42	0	NAC -sensitive
2	K373R	0.21	0	
	V216E	0.65	0	
3	R213*	0.35	0	
4	Q136E	2.68	0.12	NAC -resistant
7	Y234N	0	0.54	
	H193R	0	0.29	
	V143A	0	0.59	
10	H179Y	6.43	37.79	